Publication:
An Open-Label, Multinational, Multicenter, Phase IIIb Study with Subcutaneous Administration of Trastuzumab in Patients with HER2-Positive Early Breast Cancer to Evaluate Patient Satisfaction

Thumbnail Image

Files

Cicin et al. - 2022 - An Open-Label, Multinational, Multicenter, Phase I.pdf (602.47 KB)

Date

2022-12-30

Authors

Journal Title

Journal ISSN

Volume Title

Publisher

Research Projects

Organizational Units

Journal Issue

Abstract

Description

Keywords

breast cancer, HER2, patient satisfaction, subcutaneous, trastuzumab

Citation

URI

https://hdl.handle.net/11424/254747

Collections

Research Outputs